Oryzon Genomics Sa Stock Earnings Per Share
| ORY Stock | EUR 1.58 0.04 2.60% |
Oryzon Genomics SA fundamentals help investors to digest information that contributes to Oryzon Genomics' financial success or failures. It also enables traders to predict the movement of Oryzon Stock. The fundamental analysis module provides a way to measure Oryzon Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oryzon Genomics stock.
Oryzon |
Oryzon Genomics SA Company Earnings Per Share Analysis
Oryzon Genomics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Oryzon Genomics Earnings Per Share | (0.09) X |
Most of Oryzon Genomics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oryzon Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Oryzon Genomics SA has an Earnings Per Share of -0.088 times. This is 101.05% lower than that of the Biotechnology sector and 98.16% lower than that of the Health Care industry. The earnings per share for all Spain stocks is 102.82% higher than that of the company.
Oryzon Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oryzon Genomics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oryzon Genomics could also be used in its relative valuation, which is a method of valuing Oryzon Genomics by comparing valuation metrics of similar companies.Oryzon Genomics is currently under evaluation in earnings per share category among its peers.
Oryzon Fundamentals
| Return On Equity | -0.0685 | |||
| Return On Asset | -0.0419 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 107.12 M | |||
| Shares Outstanding | 55.56 M | |||
| Shares Owned By Insiders | 18.04 % | |||
| Shares Owned By Institutions | 0.72 % | |||
| Price To Earning | (12.98) X | |||
| Price To Book | 1.65 X | |||
| Price To Sales | 12.17 X | |||
| Gross Profit | 9.87 M | |||
| EBITDA | (6.58 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 29.11 M | |||
| Cash Per Share | 0.76 X | |||
| Total Debt | 10.35 M | |||
| Debt To Equity | 37.10 % | |||
| Current Ratio | 2.73 X | |||
| Book Value Per Share | 1.35 X | |||
| Cash Flow From Operations | (3.63 M) | |||
| Earnings Per Share | (0.09) X | |||
| Target Price | 7.77 | |||
| Number Of Employees | 43 | |||
| Beta | 1.02 | |||
| Market Capitalization | 140.29 M | |||
| Total Asset | 95.38 M | |||
| Z Score | 7.8 | |||
| Net Asset | 95.38 M |
About Oryzon Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oryzon Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oryzon Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oryzon Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Oryzon Stock
Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.